Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVERTAS-1: Switch to dolutegravir + lamivudine versus continued dolutegravir + abacavir + lamivudine in virologically suppressed HIV infection
2019-004999-19Phase 4Completed
- Sponsor
- Copenhagen University Hospital - Hvidovre
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in human immunodeficiency virus infection (HIV) comparing Continue dolutegravir + abacavir + lamivudine with Switch to dolutegravir + lamivudine (2 arms). Primary endpoint: Primary outcome: body weight change. Started Feb 2020; status: completed.
02
Drugs
dolutegravirlamivudineabacavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2019-004999-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004999-19.